Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jonathan Zalevsky Insider Profile
4 Followers
Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, holds 326.90K shares in Nektar Therapeutics (Ticker: NKTR). Most recently, Jonathan Zalevsky Sold $51,115 shares of Nektar Therapeutics on Dec 20, 2024 for an estimated value of 48.05K.
Jonathan Zalevsky Nektar Therapeutics (NKTR)Chief R&D Officer
Nektar Therapeutics (NKTR)
Chief R&D Officer
Ranked #80,927 out of 99,797 Corporate Insiders
Profitable Transactions
4 out of 9 Profitable Transactions
Average Return
-16.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jonathan Zalevsky's holdings
Insider Roles
Chief R&D Officer
Roles that Jonathan Zalevsky holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Nov 18, 2022 - Nov 18, 2023
Return:+86.20%
The most profitable trade made by Jonathan Zalevsky
Jonathan Zalevsky's Trading History
List of latest transactions for each holding click on a transaction to see Jonathan Zalevsky's performance on stock
You May Also Like
Jonathan Zalevsky insider profile FAQ
What is the percentage of profitable transactions made by Jonathan Zalevsky?
The percentage of profitable transactions made by Jonathan Zalevsky is 44%.
What is the average return per transaction made by Jonathan Zalevsky?
The average return per transaction made by Jonathan Zalevsky is -16.40%.
What stocks does Jonathan Zalevsky hold?
Jonathan Zalevsky holds: NKTR stocks.
What was Jonathan Zalevsky’s latest transaction?
Jonathan Zalevsky latest transaction was an Informative Sell of $48.05K.
What was Jonathan Zalevsky's most profitable transaction?
Jonathan Zalevsky’s most profitable transaction was an Informative Sell of NKTR stock on November 18, 2022. The return on the trade was 86.20%.
What is Jonathan Zalevsky's role in Nektar Therapeutics?
Jonathan Zalevsky's role in Nektar Therapeutics is Chief R&D Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.